P95 Julius Clinical team at AAIC 2026

The P95 Julius Clinical team recently joined researchers, sponsors, and industry leaders in London for the Alzheimer’s Association International Conference (AAIC) 2026. Across plenary presentations, late-breaking sessions, and industry discussions, several themes emerged that point toward the next generation of Alzheimer’s disease (AD) research: a deeper understanding of biological heterogeneity, growing interest in innovative trial designs, and continued momentum behind disease-modifying therapies that extend beyond amyloid.

While scientific innovation is moving quickly, discussions throughout AAIC also highlighted the importance of ensuring that advances in biomarkers, trial methodology, and therapeutics remain aligned with regulatory expectations and practical implementation in clinical development.

Alzheimer’s Disease Is Increasingly Viewed as Multiple Biological Subtypes

One of the most impactful presentations at AAIC came from Betty Tijms, whose work highlighted the growing evidence that Alzheimer’s disease is not a single, uniform condition. Building on an expanding body of research, Tijms demonstrated how cerebrospinal fluid (CSF) proteomics can identify distinct biological subtypes of Alzheimer’s disease, each characterized by different underlying disease mechanisms.

These findings reinforce the idea that Alzheimer’s disease is highly heterogeneous, with important biological differences across patients. Understanding these differences may help explain variability in disease progression, treatment response, and clinical trial outcomes, while creating opportunities for more targeted therapeutic development.

For sponsors, the implications are substantial. A more refined understanding of disease biology could help explain differences in efficacy observed across study populations. Beyond supporting the development of therapies targeting amyloid and tau, biomarker-driven patient stratification may enable more targeted trial populations, improving the ability to detect meaningful treatment effects and identify both the patients most likely to benefit from a given intervention and those at increased risk of adverse effects.

As the field moves toward precision medicine, biological subtyping is becoming increasingly important not only for drug discovery but also for trial design, patient selection, and the interpretation of clinical outcomes.

Understanding disease complexity is increasingly important as sponsors evaluate enrollment strategies and endpoint selection in Alzheimer’s studies. For additional background on the current Alzheimer’s disease landscape, download our Alzheimer’s Disease Fact Sheet.

Tau Therapeutics Continue to Gain Momentum

Another highly anticipated topic at AAIC was the presentation of topline results from Biogen’s Celia program, a study targeting tau pathology.

Although the trial did not meet its primary endpoint, the data generated considerable discussion throughout the conference because of the signals observed in both pathology and clinical outcomes. The study demonstrated reductions in tau pathology alongside indications of cognitive benefit, providing further support for tau as a potentially meaningful therapeutic target.

For the Alzheimer’s research community, these results represent another step in the industry’s broader effort to expand beyond amyloid-focused approaches. While additional studies will be needed to confirm the findings, the overall sentiment at AAIC suggested optimism about continued development and progression into Phase III evaluation.

The growing focus on tau reflects a broader trend across neuroscience: combining biological insights with targeted interventions to address the complexity of neurodegenerative disease.

As biomarkers continue to play a larger role in Alzheimer’s development programs, complementary technologies such as EEG are also helping researchers better understand disease progression and therapeutic impact. Watch our webinar on The Role of EEG in Dementia Trials.

Innovative Trial Designs Are Advancing Faster Than Regulation

Beyond therapeutic development, AAIC also featured discussions on emerging clinical trial methodologies, particularly the use of digital twins and external control arms.

Several large pharmaceutical companies presented strategies leveraging external data sources to reduce placebo requirements and potentially decrease overall sample sizes. These approaches aim to improve trial efficiency, reduce patient burden, and accelerate development timelines.

However, discussions also underscored the important reality that regulatory acceptance remains a significant consideration.

In one of the session’s concluding presentations, FDA representatives expressed caution regarding the use of digital twins and external controls as substitutes for traditional placebo groups. Concerns centered on the fact that external control populations often do not follow identical schedules, assessments, and operational conditions as participants enrolled in randomized placebo-controlled trials.

The takeaway was clear: the technology and methodology are advancing rapidly, but broad regulatory adoption has not yet fully caught up. Sponsors exploring these approaches should carefully balance innovation with regulatory expectations and engage agencies early when considering novel trial designs.

What This Means for Future Alzheimer’s Development

AAIC 2026 reinforced that Alzheimer’s research is entering a new phase defined by precision, biological insight, and methodological innovation.

Researchers are moving beyond viewing Alzheimer’s disease as a single entity and are increasingly focused on understanding distinct biological mechanisms that may influence disease progression and treatment response. At the same time, therapeutic pipelines continue to diversify, with tau-targeting programs generating encouraging signals despite the challenges that remain.

On the operational side, innovative approaches such as digital twins and external controls offer exciting possibilities for improving trial efficiency, yet regulatory alignment will remain critical for successful implementation.

For sponsors developing therapies in Alzheimer’s disease and related neurodegenerative conditions, success will increasingly depend on integrating biomarker strategies, selecting the right patient populations, and designing trials that balance scientific innovation with regulatory rigor.

Looking Ahead

The conversations at AAIC 2026 highlighted a field that is rapidly evolving, driven by advances in biomarker science, precision medicine, and novel therapeutic approaches. As these developments continue to shape clinical research, the need for thoughtful trial design and deep disease expertise becomes ever more important.

At P95 Julius Clinical, we are committed to helping sponsors translate emerging scientific insights into effective development strategies that can accelerate the delivery of meaningful therapies to patients living with Alzheimer’s disease. Connect with our experts to discuss the latest developments in Alzheimer’s disease research and clinical trial strategy.